← All themes
Theme

Medical Devices

Every analyzed stock in Medical Devices — 253 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Medical Devices risk
Near-term vs. long-term risk for this theme
⚡ Right now ?Near-term risk over roughly the next 3 months. Blends live market conditions (volatility, how far the S&P is from its highs, credit spreads, the yield curve, sentiment), how stretched valuations are, and what the smart money is doing. Higher = greater odds of a pullback. · next 0–3 months
43 /100 Elevated ▲ +1 slight
Long-term risk ?Long-term / structural risk — the market's underlying tide. Where valuations sit versus 145 years of history (Shiller CAPE) plus multi-year trends. A high reading means weak long-run return prospects even if the market feels calm right now. · structural · vs 145yr history
66 /100 High ▲ +5 mild
▲ / ▼ = change vs ~7 days ago — red = risk rising, green = falling.
Inside the "right now" score — a 45 / 30 / 25 blend · 138 stocks valued
Conditions · 45% ?The live market weather: VIX (expected volatility), how far the S&P 500 is below its 52-week high, high-yield credit spreads, the 10-year vs 2-year yield curve, and the Fear & Greed index. Market-wide indices, not per-stock.
33 Moderate
Valuation · 30% ?How expensive stocks are versus our intrinsic-value models: the median price-to-value ratio and the share of stocks trading above what we think they are worth, across 138 stocks.
51 Elevated
Smart money · 25% ?What informed money is doing: short-selling activity plus corporate insiders buying or selling their own stock. Broken out below.
45 Elevated
Smart money — the three inputs
Short-selling ?Share of ALL US trading volume that is short sales (FINRA, ~12,000 symbols, market-wide). It normally sits near 45–50%, so readings above ~50% lean bearish and read as higher risk. Weighted 40% of Smart money.
49.5%
Elevated
Buyers' strike ?Share of the sampled companies whose insiders bought NONE of their own stock on the open market in the last 12 months. The higher this runs, the more bearish (nobody's buying the dip in their own shares). Weighted 35%.
55%
Elevated
Net insider selling ?Share of the sampled companies whose insiders were net DISCRETIONARY sellers over 12 months (excludes scheduled 10b5-1 plans, which carry little signal). Around half is normal; well above that is bearish. Weighted 25%.
31%
Moderate
Black number = the raw figure; coloured bar & word = how it reads as risk. Insider inputs from 213 stocks (full universe); short-selling is market-wide.
Long-term risk: the long-term read runs high mainly because valuations sit near a historic extreme (Shiller CAPE) — a structural backdrop, not about this week.
Scale (0–100): 0–20 Low · 20–40 Moderate · 40–60 Elevated · 60–80 High · 80–100 Extreme. "Right now" reads today's conditions; the "long-term" score is anchored to ~145 years of valuation history.
Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
This week in Medical Devices
Medical Devices — Sep 7 – Sep 11, 2026 (Wk 37): Medical Device Stocks See Elevated Risk Amid Earnings and Valuation Scrutiny →
The medical devices sector experienced an increase in its risk score this week, coinciding with several companies reporting earnings and investors evaluating valuations. While some firms showed profit growth, others faced scrutiny regarding their stock prices…
ABT
ABBOTT LABORATORIES
Fairly valued
Healthcare Risk 31 · Moderate
Price$102.03
Model IV$104.52
P/IV0.82
Discount 2% Return to IV: +2.4%
Market implies +3.3%/yr vs model +4.1% · in line
ACH
ACCENDRA HEALTH INC/VA/
Valuation N/A
Industrials Risk 55 · Elevated
Price$1.08
Model IV—
P/IV—
Market implies -47.3%/yr vs model +2.0% · below model
ACONW
Aclarion, Inc.
Deeply undervalued
Healthcare Risk 36 · Moderate
Price$0.03
Model IV$0.06
P/IV0.43
Discount 57% Return to IV: +134.4%
Market implies -25.0%/yr vs model +5.9% · below model
ADGM
Adagio Medical Holdings, Inc.
Valuation N/A
Healthcare Risk 49 · Elevated
Price$0.56
Model IV—
P/IV—
Market implies +42.8%/yr vs model +15.0% · above model
AEMD
AETHLON MEDICAL INC
Valuation N/A
Healthcare Risk 43 · Elevated
Price$1.54
Model IV—
P/IV—
Market implies +15.4%/yr vs model +15.0% · in line
AIMD
Ainos, Inc.
Valuation N/A
Technology Risk 39 · Moderate
Price$1.44
Model IV—
P/IV—
Market implies +91.2%/yr vs model +2.0% · above model
ALGN
ALIGN TECHNOLOGY INC
Deeply overvalued
Healthcare Risk 70 · High
Price$147.00
Model IV$54.97
P/IV3.18
Premium +167% Return to IV: -62.6%
Market implies +18.9%/yr vs model +5.7% · above model
AMIX
Autonomix Medical, Inc.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$4.37
Model IV—
P/IV—
Limited data — see page
ANGO
ANGIODYNAMICS INC
Deeply overvalued
Healthcare Risk 53 · Elevated
Price$15.68
Model IV$6.05
P/IV1.90
Premium +159% Return to IV: -61.4%
Market implies +12.1%/yr vs model +2.0% · above model
ANIK
Anika Therapeutics, Inc.
Deeply overvalued
Healthcare Risk 51 · Elevated
Price$20.86
Model IV$7.53
P/IV1.93
Premium +177% Return to IV: -63.9%
Market implies +10.6%/yr vs model +2.0% · above model
AORT
ARTIVION, INC.
Fairly valued
Healthcare Risk 47 · Elevated
Price$25.08
Model IV$25.28
P/IV0.88
Discount 1% Return to IV: +0.8%
Market implies -7.1%/yr vs model +10.2% · below model
APT
ALPHA PRO TECH LTD
Undervalued
Healthcare Risk 42 · Elevated
Price$5.29
Model IV$7.15
P/IV0.81
Discount 26% Return to IV: +35.1%
Market implies -0.1%/yr vs model +7.0% · below model
APYX
Apyx Medical Corp
Valuation N/A
Healthcare Risk 57 · Elevated
Price$2.90
Model IV—
P/IV—
Market implies +28.5%/yr vs model +2.2% · above model
ARAY
ACCURAY INC
Valuation N/A
Healthcare Risk 44 · Elevated
Price$0.25
Model IV—
P/IV—
Market implies -50.0%/yr vs model +3.7% · below model
ATEC
Alphatec Holdings, Inc.
Deeply undervalued
Healthcare Risk 48 · Elevated
Price$10.58
Model IV$33.35
P/IV0.23
Discount 68% Return to IV: +215.2%
Market implies -23.3%/yr vs model +33.1% · below model
ATRC
AtriCure, Inc.
Undervalued
Healthcare Risk 30 · Moderate
Price$54.54
Model IV$36.20
P/IV0.76
Premium +51% Return to IV: -33.6%
Market implies +0.7%/yr vs model +18.2% · below model
AVNS
AVANOS MEDICAL, INC.
Deeply overvalued
Healthcare Risk 50 · Elevated
Price$24.99
Model IV$9.19
P/IV2.70
Premium +172% Return to IV: -63.2%
Market implies +19.1%/yr vs model +7.4% · above model
AVR
Anteris Technologies Global Corp.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$8.35
Model IV—
P/IV—
Market implies +117.9%/yr vs model +2.0% · above model
AXGN
Axogen, Inc.
Deeply overvalued
Healthcare Risk 64 · High
Price$42.16
Model IV$11.62
P/IV3.40
Premium +263% Return to IV: -72.4%
Market implies +13.2%/yr vs model +15.3% · in line
BAX
BAXTER INTERNATIONAL INC
Deeply overvalued
Healthcare Risk 73 · High
Price$23.80
Model IV$5.14
P/IV3.65
Premium +363% Return to IV: -78.4%
Market implies +24.1%/yr vs model +3.0% · above model
BBLG
Bone Biologics Corp
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.55
Model IV—
P/IV—
Limited data — see page
BBLGW
Bone Biologics Corp
Valuation N/A
Healthcare Risk 37 · Moderate
Price$4.54
Model IV—
P/IV—
Limited data — see page
BBNX
Beta Bionics, Inc.
Undervalued
Healthcare Risk 36 · Moderate
Price$16.57
Model IV$16.52
P/IV0.73
Premium +0% Return to IV: -0.3%
Market implies -1.6%/yr vs model +50.0% · below model
BDMD
Baird Medical Investment Holdings Ltd
Deeply overvalued
Healthcare Risk 50 · Elevated
Price$1.10
Model IV$0.41
P/IV3.61
Premium +167% Return to IV: -62.5%
Market implies +7.4%/yr vs model +2.0% · above model
BDMDW
Baird Medical Investment Holdings Ltd
Valuation N/A
Healthcare Risk 37 · Moderate
Price$0.04
Model IV—
P/IV—
Market implies -37.5%/yr vs model +2.0% · below model
BDX
BECTON DICKINSON & CO
Valuation N/A
Healthcare Risk 47 · Elevated
Price$177.85
Model IV—
P/IV—
Market implies +3.3%/yr vs model +5.4% · in line
BEAT
HeartBeam, Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$0.41
Model IV—
P/IV—
Limited data — see page
BEATW
HeartBeam, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$0.01
Model IV—
P/IV—
Limited data — see page
BFLY
Butterfly Network, Inc.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$7.33
Model IV—
P/IV—
Market implies +66.0%/yr vs model +11.8% · above model
BHC
Bausch Health Companies Inc.
Deeply undervalued
Healthcare Risk 41 · Elevated
Price$5.86
Model IV$45.96
P/IV0.12
Discount 87% Return to IV: +684.3%
Market implies -24.9%/yr vs model +6.5% · below model
BJDX
Bluejay Diagnostics, Inc.
Valuation N/A
Healthcare Risk 30 · Moderate
Price$0.90
Model IV—
P/IV—
Market implies +2.0%/yr vs model +15.0% · below model
BLFS
BIOLIFE SOLUTIONS INC
Valuation N/A
Healthcare Risk 31 · Moderate
Price$34.95
Model IV—
P/IV—
Market implies +51.7%/yr vs model +2.0% · above model
BME
BlackRock Health Sciences Trust
Valuation N/A
Unknown
Price$44.22
Model IV—
P/IV—
Limited data — see page
BMEZ
BlackRock Health Sciences Term Trust
Valuation N/A
Unknown
Price$16.45
Model IV—
P/IV—
Limited data — see page
BMRA
BIOMERICA INC
Valuation N/A
Healthcare Risk 28 · Moderate
Price$2.36
Model IV—
P/IV—
Market implies +27.1%/yr vs model +2.0% · above model
BSX
BOSTON SCIENTIFIC CORP
Deeply undervalued
Healthcare Risk 29 · Moderate
Price$42.98
Model IV$105.68
P/IV0.46
Discount 59% Return to IV: +145.9%
Market implies -0.7%/yr vs model +12.8% · below model
BVS
Bioventus Inc.
Deeply overvalued
Healthcare Risk 54 · Elevated
Price$13.16
Model IV$7.13
P/IV1.19
Premium +84% Return to IV: -45.8%
Market implies +13.9%/yr vs model +8.0% · above model
BWAY
Brainsway Ltd.
Valuation N/A
Healthcare Risk 38 · Moderate
Price$13.63
Model IV—
P/IV—
Limited data — see page
CARL
CARLSMED, INC.
Deeply undervalued
Healthcare Risk 31 · Moderate
Price$14.73
Model IV$17.56
P/IV0.65
Discount 16% Return to IV: +19.2%
Market implies -1.9%/yr vs model +50.0% · below model
CBLL
Ceribell, Inc.
Deeply overvalued
Healthcare Risk 55 · Elevated
Price$24.33
Model IV$8.64
P/IV2.14
Premium +182% Return to IV: -64.5%
Market implies +14.5%/yr vs model +40.3% · below model
CCM
Concord Medical Services Holdings Ltd
Valuation N/A
Healthcare Risk 28 · Moderate
Price$3.97
Model IV—
P/IV—
Market implies +14.4%/yr vs model +2.0% · above model
CDRE
Cadre Holdings, Inc.
Deeply overvalued
Healthcare Risk 64 · High
Price$28.58
Model IV$16.24
P/IV1.92
Premium +76% Return to IV: -43.2%
Market implies +14.9%/yr vs model +9.5% · above model
CERS
CERUS CORP
Deeply overvalued
Healthcare Risk 59 · Elevated
Price$2.49
Model IV$1.07
P/IV2.84
Premium +133% Return to IV: -57.0%
Market implies +14.4%/yr vs model +10.0% · above model
CLGN
CollPlant Biotechnologies Ltd
Valuation N/A
Healthcare Risk 33 · Moderate
Price$3.40
Model IV—
P/IV—
Market implies +60.5%/yr vs model +2.0% · above model
CLPT
ClearPoint Neuro, Inc.
Valuation N/A
Healthcare Risk 57 · Elevated
Price$13.72
Model IV—
P/IV—
Market implies +45.5%/yr vs model +22.7% · above model
CNMD
CONMED Corp
Undervalued
Healthcare Risk 34 · Moderate
Price$46.95
Model IV$65.94
P/IV0.54
Discount 29% Return to IV: +40.4%
Market implies +2.2%/yr vs model +9.4% · below model
CNXU
Conexeu Sciences Inc.
Valuation N/A
Healthcare Risk 51 · Elevated
Price$4.46
Model IV—
P/IV—
Limited data — see page
COCH
Envoy Medical, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$0.74
Model IV—
P/IV—
Market implies +46.9%/yr vs model +15.0% · above model
COCHW
Envoy Medical, Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$0.05
Model IV—
P/IV—
Market implies +25.0%/yr vs model +15.0% · above model
CODX
Co-Diagnostics, Inc.
Valuation N/A
Healthcare Risk 43 · Elevated
Price$1.12
Model IV—
P/IV—
Market implies +36.5%/yr vs model +2.0% · above model
COO
COOPER COMPANIES, INC.
Deeply overvalued
Healthcare Risk 45 · Elevated
Price$53.91
Model IV$44.25
P/IV1.38
Premium +22% Return to IV: -17.9%
Market implies +10.2%/yr vs model +9.2% · in line
CTSO
Cytosorbents Corp
Valuation N/A
Healthcare Risk 59 · Elevated
Price$6.41
Model IV—
P/IV—
Market implies +37.5%/yr vs model +2.0% · above model
CUPR
Cuprina Holdings (Cayman) LTD
Valuation N/A
Healthcare Risk 27 · Moderate
Price$2.93
Model IV—
P/IV—
Market implies +70.0%/yr vs model +15.0% · above model
CV
CapsoVision, Inc
Valuation N/A
Healthcare Risk 40 · Elevated
Price$6.60
Model IV—
P/IV—
Market implies +19.1%/yr vs model +15.3% · above model
CVRX
CVRx, Inc.
Deeply undervalued
Healthcare Risk 34 · Moderate
Price$2.88
Model IV$10.57
P/IV0.53
Discount 73% Return to IV: +267.2%
Market implies -24.4%/yr vs model +44.4% · below model
CVV
CVD EQUIPMENT CORP
Valuation N/A
Industrials Risk 42 · Elevated
Price$4.68
Model IV—
P/IV—
Market implies +55.0%/yr vs model +11.9% · above model
DAIO
DATA I/O CORP
Deeply overvalued
Healthcare Risk 67 · High
Price$2.77
Model IV$1.96
P/IV2.16
Premium +42% Return to IV: -29.3%
Market implies -3.5%/yr vs model +2.0% · below model
DCTH
DELCATH SYSTEMS, INC.
Fairly valued
Healthcare Risk 33 · Moderate
Price$15.91
Model IV$12.42
P/IV0.87
Premium +28% Return to IV: -21.9%
Market implies +5.0%/yr vs model +50.0% · below model
DGII
DIGI INTERNATIONAL INC
Deeply overvalued
Technology Risk 58 · Elevated
Price$69.03
Model IV$38.50
P/IV1.74
Premium +79% Return to IV: -44.2%
Market implies +16.1%/yr vs model +9.7% · above model
DH
Definitive Healthcare Corp.
Fairly valued
Technology Risk 40 · Elevated
Price$1.05
Model IV$0.95
P/IV0.98
Premium +10% Return to IV: -9.3%
Market implies +7.6%/yr vs model +10.5% · in line